Uscom ends 2016 with record manufacturing
January 3rd, 2017
Uscom today notified the market that Uscom manufactured record numbers of USCOM 1A devices for the month of December 2016 and for the first half of FY 2017 to meet orders into Chinese, European and US clinical markets. In addition Uscom completed the manufacture of its 1,000th USCOM 1A cardiovascular monitor.
Uscom manufactured a record number of USCOM 1A units for the month of December 2016, and in the second quarter of FY 2017. December quarterly manufacturing represented 42% of the total devices manufactured annually in FY 2016. The number of units manufactured in the first half of FY 2017 increased by 28% on the previous half and Uscom delivered its 1000th USCOM 1A device into global markets.
Uscom is anticipating the sequential commercial release of its new BP+ and BP+ Reporter and SpiroSonic series of devices and the accompanying SpiroReporter software into the Chinese, European and US markets over the next twelve months as regulatory permissions are received. CE approval for the SpiroSonic devices was received last month, with other approvals at various stages of preparation, submission and review. To date all revenue and revenue growth has predominantly been attributable to USCOM 1A sales.
Executive Chairman of Uscom, Associate Professor Rob Phillips said “Uscom is a milestone driven company, and despite complex global dynamics we are continuing our outstanding growth trends into the 5th consecutive year. We are currently preparing for the manufacture and sale of the BP+ and SpiroSonic series of devices into global markets as regulatory approvals are granted. This will involve transitioning to volume manufacturing to meet the current increased demand and the anticipated new demand; a change that will improve supply and margins. It’s really satisfying that our USCOM 1A device is now being adopted world wide in significant numbers to save the lives of children and adults, and remains an innovative cornerstone of advanced haemodynamics – we have effectively changed clinical practice. We anticipate the BP+ and SpiroSonic devices will do the same in complimentary clinical settings and start significantly contributing to revenue over the next 12 months.”
Uscom is the manufacturer of the USCOM 1A, the Uscom BP+, and Uscom SpiroSonic digital ultrasonic spirometry technologies. These premium digital devices are sold into global medical markets, changing the way clinician diagnose and treat cardiovascular and pulmonary diseases, including hypertension, heart failure, asthma, COPD and sleep disorders. The products are integral for optimising management of sepsis, guidance of fluid, inotropes and vasoactive therapies in critical care monitoring, for advanced monitoring of hypertension and pre-eclampsia, and in clinical and home care asthma and COPD monitoring.
Uscom Awarded Euro Grant for Lung Cancer Diagnostic
November 28th, 2016
Uscom today notified the market that Uscom was a member of a consortium awarded 2.2m Euro (AU$3.1m) over 3 years to develop a new Exhaled Breath Condensate (EBC) device and system for early diagnosis of lung cancer. The grant was made by the Hungarian National Research, Development and Innovation Office to a consortium which included Uscom Europe, the Material Sciences Department of the Hungarian Academy of Sciences, and the Medical School of the Semmelweis University in Budapest, Hungary. The total value of the project is 2.7m Euro (AU$3.8m) and Uscom will receive 300k Euro (AU$427k) in the first stage of the project.
The project is titled “Material research and development for the implementation of extracellular vesicular based medical diagnostics”, and Uscom’s contribution involves the development of a novel EBC device, using advanced technology derived from experience in developing and manufacturing digital ultrasonic spirometers and respiratory monitoring devices. The EBC device is conceived to extract condensate from the exhaled breath from which exosomes can be isolated. The Exosomes, which contain RNA, lipids, proteins and metabolites which reflect the type of cell from which they originate, can then be analysed to identify a wide variety of diseases. The application of these exosomes as biomarkers has proven particularly promising for the early detection of lung and other cancers, and cystic fibrosis. The field is complex and rapidly evolving and an improved method of isolating exosomes for analysis has many potential diagnostic, therapeutic commercial opportunities.
The project also depends on the development of novel polymers for lining the EBC device so extraction of the samples from the expired breath can be made efficient. This will be researched by the Hungarian Academy of Science team, while the clinical testing of the device and methods will be overseen by the team from Semmelweis University Medical Faculty. This project will result in Uscom owned IP and a right of first refusal for any other IP developed in the project over the 3 years.
Executive Chairman of Uscom, Associate Professor Rob Phillips, a co-author of the project, said “Development of efficient methods for early and accurate detection of lung cancer and a wide range of viral, microbial, neoplastic (cancer) and genetic diseases from a simple breath test may lead to widespread population screening. Exosome study is a rapidly growing focus of medical science, and this grant from the Hungarian Government is recognition of the quality of science within Uscom, and its proven expertise in technology development. This research may also generate a new generation of medical devices with potentially life saving applications and global commercial application and may result in a pipeline of new devices for Uscom just as we bring our new BP+ and SpiroSonic devices to market. This collaboration also establishes a relationship between Uscom Europe and two of the most respected medical and science research centres in Europe.“
Uscom is the manufacturer of the USCOM 1A, the Uscom BP+, and Uscom SpiroSonic digital ultrasonic spirometry technologies and distributes and sells these devices worldwide. These premium digital devices are changing the way clinician diagnose and treat cardiovascular and pulmonary diseases, including hypertension, heart failure, asthma, COPD and sleep disorders. The products are integral for optimising management of sepsis, guidance of fluid, inotropes and vasoactive therapies in critical care monitoring, for advanced monitoring of hypertension and pre-eclampsia, and in clinical and home care asthma and COPD monitoring.
Uscom CEO Appointed to Govt China Initiative
November 7th, 2016
Uscom Engaged in Development of NSW Health China Strategy
Uscom has announced to market the appointment of Uscom CEO Assoc. Professor Rob Phillips to the NSW Health China Advisory Group. The Advisory Group includes a number of leading Australian academics and entrepreneurs with high level China experience, and is the initiative of the NSW Health Minister, the Hon Jillian Skinner.
The Group will act to develop and guide NSW Health in an active strategy of engagement and exchange with Chinese academics and entrepreneurs and to lead commercial and educational opportunities between Australia and China.
Uscom is a Sydney based developer and manufacturer of advanced medical technologies specialising in cardiovascular and pulmonary monitoring and improved circulatory management, with regional offices in Shanghai, Budapest, London and Los Angeles.
Prof Phillips frequently visits China for educational exchanges at Chinese Hospitals, and delivers in the order of 40 lectures annually in Chinese Universities and Hospitals to China’s leading critical care clinicians on the subject of circulation and cardiovascular medicine. Prof Phillips has an appointment with the Critical Care Research Group In the Department of Medicine at the University of Queensland and delivers remote lectures and clinical demonstrations via digital media into various Chinese centres from Australia, and the presentation are syndicated into remote tertiary medical teaching centres throughout China.
Uscom CEO Associate Professor Rob Phillips said, “China is a huge and growing market with increasing complexity, and Uscom has many good relationships there established over many years. The Chinese people expect the best standards of clinical care, and the Chinese Government are committed to providing that, and a substantial portion of Uscom’s global revenues are derived from this market. This initiative by Minister Skinner and NSW Health is particularly prescient, as global politics becomes less predictable making regional commercial and academic relationships vital for Australia’s commercial growth and stability. Uscom technology is world leading with proven life saving capabilities and so the education of clinicians on advanced circulatory monitoring and management is integral to the adoption of our devices and the delivery of their life saving benefits. The USCOM 1A continues to grow in importance for management of fluid, heart failure and hypertension, while our new SpiroSonic and BP+ devices will shift the clinical management of asthma, COPD, occupational lung disease, hypertension and vascular health. China is important for Uscom’s growth, and is targeted to deliver revenue and profit for shareholders for the years ahead.”
Uscom manufactures and markets the USCOM 1A advanced haemodynamic monitor, the Uscom BP+ central blood pressure monitor, and the Uscom SpiroSonic digital ultrasonic spirometry devices. These premium digital devices are changing the way we diagnose and treat cardiovascular and pulmonary diseases, including hypertension, heart failure, asthma, COPD and sleep disorders. These products are integral for optimising management of sepsis, guidance of fluid, inotropes and vasoactive therapies in critical care monitoring, and in clinical and home care asthma and COPD monitoring.